{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:35:23Z","timestamp":1790645723570,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T00:00:00Z","timestamp":1623283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10792-021-01885-z","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T19:07:53Z","timestamp":1623352073000},"page":"3191-3198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prophylactic effect of brinzolamide\u2013brimonidine fixed combination on intraocular pressure spikes after intravitreal anti-VEGF injections"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7610-7723","authenticated-orcid":false,"given":"Maria","family":"Dettoraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Rapti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Fragkos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Theiopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthi","family":"Legaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gkounta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Anyfantaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frini","family":"Riga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"1885_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.2147\/OPTH.S17423","volume":"5","author":"F Bandello","year":"2011","unstructured":"Bandello F, De Benedetto U, Knutsson KA et al (2011) Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema. Clin Ophthalmol 5:1303\u20131308","journal-title":"Clin Ophthalmol"},{"key":"1885_CR2","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1056\/NEJMoa054481","volume":"355","author":"PJ Rosenfeld","year":"2006","unstructured":"Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419\u20131431","journal-title":"N Engl J Med"},{"key":"1885_CR3","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1136\/bjo.2007.130260","volume":"92","author":"L Arias","year":"2008","unstructured":"Arias L, Planas N, Prades S et al (2008) Intravitreal bevacizumab (Avastin) for choroidal neovascularisation secondary to pathological myopia: 6-month results. Br J Ophthalmol 92:1035\u20131039","journal-title":"Br J Ophthalmol"},{"key":"1885_CR4","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/IAE.0b013e31802eff83","volume":"27","author":"RA Costa","year":"2007","unstructured":"Costa RA, Jorge R, Calucci D et al (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 27:141\u2013149","journal-title":"Retina"},{"key":"1885_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/sj.eye.6702938","volume":"23","author":"SJ Bakri","year":"2009","unstructured":"Bakri SJ, Pulido JS, McCannel CA et al (2009) Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 23:181\u2013185","journal-title":"Eye (Lond)"},{"key":"1885_CR6","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1056\/NEJMoa062655","volume":"355","author":"DM Brown","year":"2006","unstructured":"Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432\u20131444","journal-title":"N Engl J Med"},{"key":"1885_CR7","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/eye.2014.180","volume":"28","author":"CD Murray","year":"2014","unstructured":"Murray CD, Wood D, Allgar V et al (2014) Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration-the role of oral acetazolamide in protecting glaucoma patients. Eye (Lond) 28:1218\u20131222","journal-title":"Eye (Lond)"},{"key":"1885_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ophtha.2018.11.019","volume":"126","author":"A Hoguet","year":"2019","unstructured":"Hoguet A, Chen PP, Junk AK et al (2019) The effect of anti-vascular endothelial growth factor agents on intraocular pressure and glaucoma: a report by the American Academy of ophthalmology. Ophthalmology 126:611\u2013622","journal-title":"Ophthalmology"},{"key":"1885_CR9","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/jamaophthalmol.2015.186","volume":"133","author":"SB Bressler","year":"2015","unstructured":"Bressler SB, Almukhtar T, Bhorade A et al (2015) Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 133:589\u2013597","journal-title":"JAMA Ophthalmol"},{"key":"1885_CR10","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/jamaophthalmol.2017.0059","volume":"135","author":"BD Eadie","year":"2017","unstructured":"Eadie BD, Etminan M, Carleton BC et al (2017) Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery. JAMA Ophthalmol 135:363\u2013368","journal-title":"JAMA Ophthalmol"},{"key":"1885_CR11","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3928\/15428877-20120618-01","volume":"43","author":"SE Skalicky","year":"2012","unstructured":"Skalicky SE, Ho I, Agar A et al (2012) Glaucoma filtration surgery following sustained elevation of intraocular pressure secondary to intravitreal anti-VEGF injections. Ophthalmic Surg Lasers Imaging 43:328\u2013334","journal-title":"Ophthalmic Surg Lasers Imaging"},{"key":"1885_CR12","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.survophthal.2017.08.008","volume":"63","author":"P Bracha","year":"2018","unstructured":"Bracha P, Moore NA, Ciulla TA et al (2018) The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: a review. Surv Ophthalmol 63:281\u2013295","journal-title":"Surv Ophthalmol"},{"key":"1885_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jfo.2012.02.009","volume":"35","author":"H El Chehab","year":"2012","unstructured":"El Chehab H, Le Corre A, Giraud JM et al (2012) Efficacy of prophylactic treatment of intraocular pressure spikes due to intravitreal injections. J Fr Ophtalmol 35:614\u2013621","journal-title":"J Fr Ophtalmol"},{"key":"1885_CR14","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1136\/bjophthalmol-2018-312603","volume":"103","author":"T Felfeli","year":"2019","unstructured":"Felfeli T, Hostovsky A, Trussart R et al (2019) Hypotensive efficacy of topical brimonidine for intraocular pressure spikes following intravitreal injections of antivascular endothelial growth factor agents: a randomised crossover trial. Br J Ophthalmol 103:1388\u20131394","journal-title":"Br J Ophthalmol"},{"key":"1885_CR15","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/IJG.0b013e3182948476","volume":"23","author":"BY Katayama","year":"2014","unstructured":"Katayama BY, Bonini-Filho MA, Messias AM et al (2014) Comparison of acetazolamide, brimonidine, and anterior chamber paracentesis for ocular hypertension control after initial intravitreal bevacizumab injection: a randomized clinical trial. J Glaucoma 23:461\u2013463","journal-title":"J Glaucoma"},{"key":"1885_CR16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1055\/s-0029-1245201","volume":"227","author":"PE Theoulakis","year":"2010","unstructured":"Theoulakis PE, Lepidas J, Petropoulos IK et al (2010) Effect of brimonidine\/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd 227:280\u2013284","journal-title":"Klin Monbl Augenheilkd"},{"key":"1885_CR17","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.ophtha.2014.06.022","volume":"121","author":"T Aung","year":"2014","unstructured":"Aung T, Laganovska G, Hernandez Paredes TJ et al (2014) Twice-daily brinzolamide\/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology 121:2348\u20132355","journal-title":"Ophthalmology"},{"key":"1885_CR18","first-page":"2201","volume":"9","author":"S Sharma","year":"2015","unstructured":"Sharma S, Trikha S, Perera SA et al (2015) Clinical effectiveness of brinzolamide 1%-brimonidine 0.2% fixed combination for primary open-angle glaucoma and ocular hypertension. Clin Ophthalmol 9:2201\u20132207","journal-title":"Clin Ophthalmol"},{"key":"1885_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3129\/i07-172","volume":"42","author":"H Hollands","year":"2007","unstructured":"Hollands H, Wong J, Bruen R et al (2007) Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 42:807\u2013811","journal-title":"Can J Ophthalmol"},{"key":"1885_CR20","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.ajo.2008.07.007","volume":"146","author":"JE Kim","year":"2008","unstructured":"Kim JE, Mantravadi AV, Hur EY et al (2008) Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 146:930\u2013934","journal-title":"Am J Ophthalmol"},{"key":"1885_CR21","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1136\/bjo.2007.126193","volume":"92","author":"G Mojica","year":"2008","unstructured":"Mojica G, Hariprasad SM, Jager RD et al (2008) Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol 92:584","journal-title":"Br J Ophthalmol"},{"key":"1885_CR22","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s10792-020-01667-z","volume":"41","author":"N Shoeibi","year":"2021","unstructured":"Shoeibi N, Ghosi Z, Jafari H et al (2021) Effect of antiglaucoma agents on short-term intraocular pressure fluctuations after intravitreal bevacizumab injections. Int Ophthalmol 41:1081\u20131090","journal-title":"Int Ophthalmol"},{"key":"1885_CR23","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1001\/archophthalmol.2010.297","volume":"128","author":"MP Frenkel","year":"2010","unstructured":"Frenkel MP, Haji SA, Frenkel RE (2010) Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol 128:1523\u20131527","journal-title":"Arch Ophthalmol"},{"key":"1885_CR24","doi-asserted-by":"publisher","first-page":"771","DOI":"10.5301\/ejo.5000455","volume":"24","author":"P Carnota-Mendez","year":"2014","unstructured":"Carnota-Mendez P, Mendez-Vazquez C, Otero-Villar J et al (2014) Effect of prophylactic medication and influence of vitreous reflux in pressure rise after intravitreal injections of anti-VEGF drugs. Eur J Ophthalmol 24:771\u2013777","journal-title":"Eur J Ophthalmol"},{"key":"1885_CR25","doi-asserted-by":"publisher","first-page":"919","DOI":"10.2165\/00002512-200320120-00008","volume":"20","author":"RS Cvetkovic","year":"2003","unstructured":"Cvetkovic RS, Perry CM (2003) Brinzolamide: a review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 20:919\u2013947","journal-title":"Drugs Aging"},{"key":"1885_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2165\/00002512-199812030-00005","volume":"12","author":"JC Adkins","year":"1998","unstructured":"Adkins JC, Balfour JA (1998) Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging 12:225\u2013241","journal-title":"Drugs Aging"},{"key":"1885_CR27","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/CRD.0b013e318156ec64","volume":"16","author":"JA Han","year":"2008","unstructured":"Han JA, Frishman WH, Wu Sun S et al (2008) Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension. Cardiol Rev 16:95\u2013108","journal-title":"Cardiol Rev"},{"key":"1885_CR28","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1080\/02713680902989337","volume":"34","author":"I Kaiserman","year":"2009","unstructured":"Kaiserman I, Fendyur A, Vinker S (2009) Topical beta blockers in asthmatic patients-is it safe? Curr Eye Res 34:517\u2013522","journal-title":"Curr Eye Res"},{"key":"1885_CR29","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.ophtha.2005.01.042","volume":"112","author":"R van der Valk","year":"2005","unstructured":"van der Valk R, Webers CA, Schouten JS et al (2005) Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology 112:1177\u20131185","journal-title":"Ophthalmology"},{"key":"1885_CR30","first-page":"1131","volume":"10","author":"A Pece","year":"2016","unstructured":"Pece A, Allegrini D, Montesano G et al (2016) Effect of prophylactic timolol 0.1% gel on intraocular pressure after an intravitreal injection of ranibizumab: a randomized study. Clin Ophthalmol 10:1131\u20131138","journal-title":"Clin Ophthalmol"},{"key":"1885_CR31","doi-asserted-by":"publisher","first-page":"6214","DOI":"10.1167\/iovs.12-9875","volume":"53","author":"JM Martinez-de-la-Casa","year":"2012","unstructured":"Martinez-de-la-Casa JM, Ruiz-Calvo A, Saenz-Frances F et al (2012) Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab. Invest Ophthalmol Vis Sci 53:6214\u20136218","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-01885-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-021-01885-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-021-01885-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T17:09:30Z","timestamp":1628960970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-021-01885-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,10]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1885"],"URL":"https:\/\/doi.org\/10.1007\/s10792-021-01885-z","relation":{},"ISSN":["0165-5701","1573-2630"],"issn-type":[{"value":"0165-5701","type":"print"},{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,10]]},"assertion":[{"value":"3 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Informed consent for publication of their data and photographs was obtained from the patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was obtained from the Ethics Committee of \u201cElpis\u201d General Hospital, Athens, Greece (approval number 1992).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"ClinicalTrials.gov Identifier: NCT04523844, August 24, 2020, retrospectively registered.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trials registration"}}]}}